US2006275777A1PendingUtilityA1

Novel strategies for protein vaccines

23
Individually held — no corporate assignee on recordPriority: Jun 3, 2005Filed: Jun 3, 2005Published: Dec 7, 2006
Est. expiryJun 3, 2025(expired)· nominal 20-yr term from priority
Inventors:Ernst Waelti
A61K 39/001106A61K 39/0011
23
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A prerequisite for clinical vaccines is the construction of safe and highly immunogenic reagents able to generate efficient immune responses against target antigens. Lipid based delivery vesicles, including virosomes, as clinically approved safe vaccines, can be used to elicit both humoral and cell-mediated responses against protein antigens and mediate effective immune responses against the target pathogen and/or induce tumor rejection. Thus the compositions of the present invention are useful either as a primary vaccination or as a boost in combination with other vaccines in a context of an adjuvant treatment plan.

Claims

exact text as granted — not AI-modified
1 . An immunostimulatory composition comprising a protein antigen linked to the surface of a lipid-based vesicle.  
     
     
         2 . The composition of  claim 1 , wherein said protein antigen is selected from the group consisting of tumor, viral, heatshock and pathogenic proteins.  
     
     
         3 . The composition of  claim 1 , wherein said protein antigen comprises at least 25 amino acid residues.  
     
     
         4 . The composition of  claim 1 , wherein said protein antigen is covalently linked to the surface of said lipid-based vesicle.  
     
     
         5 . The composition of  claim 1 , wherein said protein antigen is linked to the surface of said lipid-based vesicle by palmitoylation.  
     
     
         6 . The composition of  claim 1 , wherein said protein antigen is noncovalently linked to the surface of said lipid-based vesicle.  
     
     
         7 . The composition of  claim 1 , wherein said protein antigen is truncated.  
     
     
         8 . The composition of  claim 1 , wherein said protein antigen comprises the extracellular domain of Her-2/neu.  
     
     
         9 . The composition of  claim 1 , wherein said lipid-based vesicle is selected from the group consisting of virosomes, IRIVs, liposomes, and iscoms.  
     
     
         10 . The composition of  claim 8 , wherein said lipid based vesicle is a virosome.  
     
     
         11 . The composition of  claim 9 , wherein said protein antigen is covalently linked to the surface of said virosome.  
     
     
         12 . The composition of  claim 9 , wherein said protein antigen is linked to the surface of said virosome by palmitoylation etc.  
     
     
         13 . The composition of  claim 9 , wherein said protein antigen is noncovalently linked to the surface of said virosome.  
     
     
         14 . The composition of  claim 9 , wherein said protein antigen is selected from the group consisting of tumor, viral, heatshock and pathogenic proteins.  
     
     
         15 . The composition of  claim 9 , wherein said protein antigen is truncated.  
     
     
         16 . The composition of  claim 9 , wherein said protein antigen comprises the extracellular domain of Her-2/neu.  
     
     
         17 . A method of generating therapeutically effective anti-tumor immune responses comprising administering to a subject the composition of  claim 1 .  
     
     
         18 . A method of generating therapeutically effective anti-viral immune responses comprising administering to a subject the composition of  claim 1.

Join the waitlist — get patent alerts

Track US2006275777A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.